{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:48:58Z","timestamp":1775670538477,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The association between the administration of sodium\u2013glucose cotransporter 2 inhibitors (SGLT2is) during acute kidney injury (AKI) and the incidence of major adverse kidney events (MAKEs) is not known.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included patients with AKI and compared the outcomes for those who were treated with SGLT2is during hospitalization and those without SGLT2i treatment. The associations of SGLT2i use with MAKEs at 10 and 30\u201390\u00a0days, each individual MAKE component, and the pre-specified patient subgroups were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 2021 to 2023, 374 patients were included in the study\u2014316 without SGLT2i use and 58 with SGLT2i use. Patients who were treated with SGLT2is were older; had a greater prevalence of diabetes, hypertension, chronic heart failure, and chronic kidney disease; required hemodialysis less often; and presented stage 3 AKI less frequently than those who were not treated with SGLT2is. Logistic regression analysis with nearest-neighbor matching revealed that SGLT2i use was not associated with the risk of MAKE10 (OR 1.08 [0.45\u20132.56]) or with MAKE30\u201390 (OR 0.76 [0.42\u20131.36]). For death, the stepwise approach demonstrated that SGLT2i use was associated with a reduced risk (OR 0.08; 0.01\u20130.64), and no effect was found for kidney replacement therapy (KRT). The subgroups of patients who experienced a reduction in the risk of MAKEs in patients with AKI treated with SGLT2is were those older than 61\u00a0years, those with an eGFR &amp;gt;81, and those without a history of hypertension or DM (<jats:italic>p<\/jats:italic> \u2264 0.05 for all).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of SGLT2is during AKI had no effect on short- or medium-term MAKEs, but some subgroups of patients may have experienced benefits from SGLT2i treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1356991","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T11:19:53Z","timestamp":1718191193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["SGLT2i treatment during AKI and its association with major adverse kidney events"],"prefix":"10.3389","volume":"15","author":[{"given":"Luz","family":"Alcantar-Vallin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose J.","family":"Zaragoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bladimir","family":"D\u00edaz-Villavicencio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Hernandez-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahir R.","family":"Camacho-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Perez-Venegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar J.","family":"Carmona-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa N.","family":"Oseguera-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Murguia-Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gael","family":"Ch\u00e1vez-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Arredondo-Dubois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Orozco-Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A.","family":"G\u00f3mez-Fregoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco G.","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Navarro-Blackaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Medina-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mart\u00ednez Gallardo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela J.","family":"Abundis-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olynka","family":"Vega-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Ch\u00e1vez-I\u00f1iguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1111\/DOM.14694","article-title":"Empagliflozin and incidence of events consistent with acute kidney injury: pooled safety analysis in more than 15 000 individuals","volume":"24","author":"Agarwal","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.34067\/KID.0000000000000250","article-title":"Outcomes associated with sodium-glucose cotransporter-2 inhibitor use in acute heart failure hospitalizations complicated by AKI","volume":"4","author":"Aklilu","year":"2023","journal-title":"Kidney360"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.26502\/anu.2644-2833047","article-title":"The use of SGLT2 inhibitors in peritoneal dialysis patients: a shade of light on dapagliflozin","volume":"5","author":"Alhwiesh","year":"2022","journal-title":"Archives Nephrol. Urology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/S40620-022-01505-8","article-title":"Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project","volume":"36","author":"Alkas","year":"2023","journal-title":"J. Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/S11892-021-01442-Z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr. Diab Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/JOURNAL.PMED.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000363725","article-title":"Clinical trial endpoints in acute kidney injury","volume":"127","author":"Billings","year":"2014","journal-title":"Nephron Clin. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000505144","article-title":"Renal anti-fibrotic effect of sodium glucose cotransporter 2 inhibition in angiotensin II-dependent hypertension","volume":"51","author":"Castoldi","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.34067\/KID.0006592021","article-title":"Global perspectives in acute kidney injury: Mexico","volume":"3","author":"Ch\u00e1vez-\u00cd\u00f1iguez","year":"2022","journal-title":"Kidney360"},{"key":"B13","doi-asserted-by":"publisher","first-page":"E230453","DOI":"10.1001\/JAMANETWORKOPEN.2023.0453","article-title":"Sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and the incidence of acute kidney injury in taiwan","volume":"6","author":"Chung","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/DOM.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3390\/biomedicines11071908","article-title":"Efficacy and safety of the use of SGLT2 inhibitors in patients on incremental hemodialysis: maximizing residual renal function, is there a role for SGLT2 inhibitors?","volume":"11","author":"De La Flor","year":"2023","journal-title":"Biomedicines"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e83353","DOI":"10.7554\/ELIFE.83353","article-title":"Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome","volume":"12","author":"Ge","year":"2023","journal-title":"Elife"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1111\/DOM.13754","article-title":"Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials","volume":"21","author":"Gilbert","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2215\/cjn.14231021","article-title":"Dapagliflozin and kidney outcomes in hospitalized patients with COVID-19 infection: an analysis of the DARE-19 randomized controlled trial","volume":"17","author":"Heerspink","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMOA2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/S12933-018-0695-Y","article-title":"Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy","volume":"17","author":"Irace","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kint.2019.04.005","article-title":"Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?","volume":"96","author":"Kanda","year":"2019","journal-title":"Kidney Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2215\/CJN.01250119","article-title":"Quality improvement goals for acute kidney injury","volume":"14","author":"Kashani","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/KISUP.2012.1","article-title":"Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/S12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2215\/CJN.01180119","article-title":"IDEAL-ICU in context","volume":"14","author":"Leaf","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/J.EKIR.2021.05.022","article-title":"Markers of kidney injury, inflammation, and fibrosis associated with ertugliflozin in patients with CKD and diabetes","volume":"6","author":"Liu","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/S13054-023-04481-Y","article-title":"Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study","volume":"27","author":"M\u00e5rtensson","year":"2023","journal-title":"Crit. Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/JAMACARDIO.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1002983","DOI":"10.1371\/JOURNAL.PMED.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined","volume":"2","author":"Meraz-Munoz","year":"2021","journal-title":"Kidney360"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/ANNRHEUMDIS-2022-222512","article-title":"SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection","volume":"81","author":"Morales","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/DOM.14018","article-title":"A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes","volume":"22","author":"Mulder","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S41100-016-0043-1\/TABLES\/2","article-title":"Renal replacement therapy for acute kidney injur","volume":"2","author":"Negi","year":"2016","journal-title":"Ren. Replace. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/J.AJKD.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of sglt2 inhibitor therapy","volume":"16","author":"Palmer","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2350050","DOI":"10.1001\/jamanetworkopen.2023.50050","article-title":"Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease","volume":"7","author":"Pan","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1014241","DOI":"10.3389\/fneph.2022.1014241","article-title":"Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients","volume":"2","author":"Pham","year":"2022","journal-title":"Front. Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/S12933-022-01455-2","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis","volume":"21","author":"Salah","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/J.EKIR.2021.05.035","article-title":"Adaptive response as a potential key link between SGLT2 inhibition and renoprotection","volume":"6","author":"Sasako","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/NDT\/GFY294","article-title":"Predicting kidney failure risk after acute kidney injury among people receiving nephrology clinic care","volume":"35","author":"Sawhney","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"B43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/J.KINT.2022.05.031","article-title":"Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors","volume":"102","author":"Suzuki","year":"2022","journal-title":"Kidney Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/J.CMET.2020.06.020","article-title":"SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1681\/ASN.2015010006","article-title":"Failed tubule recovery, AKI-CKD transition, and kidney disease progression","volume":"26","author":"Venkatachalam","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3265\/NEFROLOGIA.2009.29.S.E.NOID.3.FREE","article-title":"Declaraci\u00f3n de la Iniciativa STROBE (Strengthening the Reporting of Observational studies in Epidemiology): directrices para la comunicaci\u00f3n de estudios observacionales","volume":"29","author":"von Elm","year":"2009","journal-title":"Nefrolog\u00eda"},{"key":"B48","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/S41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1053\/j.ajkd.2022.10.012","article-title":"Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified delphi process","volume":"81","author":"Watson","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 inhibitors: physiology and Pharmacology","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.2337\/dc20-1588","article-title":"Glycemic control and the risk of acute kidney injury in patients with type 2 diabetes and chronic kidney disease: parallel population-based cohort studies in U.S. and Swedish routine care","volume":"43","author":"Xu","year":"2020","journal-title":"Diabetes Care"},{"key":"B52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2215\/CJN.11220720","article-title":"Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury","volume":"16","author":"Zhao","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1356991\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T11:19:57Z","timestamp":1718191197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1356991\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":50,"alternative-id":["10.3389\/fphar.2024.1356991"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1356991","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"article-number":"1356991"}}